Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options

Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data Patients will continue to have no out-of-pocket costs for the medication INDIANAPOLIS , Feb. 10, 2022 /PRNewswire/ --  Eli Lilly and Company  (NYSE: LLY) today announced an agreement with the U.S.